2-oxiranylpyridine | 55967-94-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-oxiranylpyridine
• 英文别名: 2-(oxiran-2-yl)pyridine；2-pyridyloxirane；2-(2-oxiranyl)pyridine；pyridin-2-yl-oxirane
• CAS: 55967-94-7
• 化学式: C₇H₇NO
• mdl: MFCD11593140
• 分子量: 121.139
• InChiKey: DVZRYTWXFWRYPT-UHFFFAOYSA-N

物化性质

• 沸点：
  227.6±20.0 °C(Predicted)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-oxiranylpyridine 在 platinum(IV) oxide 盐酸 、 氢氧化钾 、 氢气 、 sodium hydride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 erythro-1-(phenoxymethyl)-3,5,6,7,8,8a-hexahydro-1H-oxazolo<3,4-a>pyridine
  参考文献：
  名称：

  Synthesis and .beta.-adrenergic antagonism of 2-(aryloxy)-1-(2-piperidyl)ethanols

  摘要：

  A series of erythro- and threo-2-(aryloxy)-1-(2-piperidyl)ethanol derivatives (3) was synthesized from 2-(2-oxiranyl)pyridine for evaluation as beta-antagonists. Most compounds displayed high competitive beta-blocking potency, but they lacked significant beta 1/beta 2 selectivity. The 1-naphthoxy derivative erythro-3b was 17 (beta 1) and 33 (beta 2) times more potent than its open-chain analogue, propranolol. Within the whole series, erythro-3 diastereomers were more potent beta-blockers than the threo-3 isomers, and the potency of the latter seems to be rather insensitive to structural modification. The effect of N-methylation and of interposition of an alkyl chain between the aromatic ring and the side chain, while being detrimental to beta-blocking activity, was less marked than in the classic (aryloxy)propanolamine blockers.

  DOI：

  10.1021/jm00119a011
• 作为产物：
  描述：

  2-乙烯基吡啶 在 2-吡啶甲酸 、 manganese(II) triflate 作用下， 以 乙腈 为溶剂， 反应 0.08h， 生成 2-oxiranylpyridine
  参考文献：
  名称：

  锰（II）/吡啶甲酸催化烯烃的环氧化反应

  摘要：

  基于Mn（CF 3 SO 3）2，吡啶甲酸和过氧乙酸的原位生成的催化剂体系在0°C下于<5分钟内将大量烯烃转化为环氧化物，具有显着的氧化效率并且没有自由基的迹象行为。竞争实验表明，一种亲电子活性氧化剂被认为是高价Mn = O物种。配体探索表明，一般的配体球基序有助于有效氧化。该方法以其简单性和使用廉价试剂来快速获得高附加值产品而得到强调。

  DOI：

  10.1021/acs.orglett.6b00518

文献信息

• New benzoyl piperidine compounds
  申请人：——

  公开号：US20040044033A1

  公开（公告）日：2004-03-04

  Provided herein are racemic or enantiomerically enriched benzoyl piperidine compounds and pharmaceutically useful salts thereof, pharmaceutical compositions comprising an effective amount of racemic or enantiomerically enriched benzoyl piperidine compounds to treat central nervous system diseases and methods of treating central nervous system diseases in a mammal, in particular psychoses and cognition disorders.

  提供本申请中的是外消旋或enantioselectively富集的苯甲酰哌啶化合物及其药用盐,药物组合物包括用于治疗中枢神经系统疾病的racemic或enantioselectively富集的苯甲酰哌啶化合物的有效量,以及治疗哺乳动物中枢神经系统疾病的方法,特别是精神疾病和认知障碍。
• Pyrimidine derivatives useful as inhibitors of PKC-theta
  申请人：Barbosa J.M. Antonio

  公开号：US20060025433A1

  公开（公告）日：2006-02-02

  Disclosed are novel compounds of formula (I): wherein X, Y, R 1 , R 2 and R 3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  披露了公式(I)的新颖化合物：其中X、Y、R1、R2和R3如本文所述定义，它们作为PKC-theta的抑制剂是有用的，因此可用于治疗通过PKC-theta活性介导或维持的多种疾病和失调，包括免疫失调和II型糖尿病。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的方法以及在这些过程中有用的中间体。
• 5- substituted tetralones as inhibitors of ras farnesyl trransferase
  申请人：——

  公开号：US20040044057A1

  公开（公告）日：2004-03-04

  The present invention provides novel 5-substituted tetralones of Formulas (I), (II), (III) and (IV) and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme. 1

  本发明提供了式(I)、(II)、(III)和(IV)的新型5-取代四酮及其药学上可接受的盐、酯、酰胺和前药，用于治疗和预防组织的不受控制或异常增殖，如癌症、动脉粥样硬化、再狭窄和银屑病。具体而言，本发明涉及抑制法尼基转移酶酶的化合物。
• COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION
  申请人：Medivation Technologies, Inc.

  公开号：US20150266884A1

  公开（公告）日：2015-09-24

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α 2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α 1B . The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

  氢化吡啶并[4,3-b]吲哚，吡啶[3,4-b]吲哚和氮杂七元[4,5-b]吲哚被描述。这些化合物可能与肾上腺素受体α2B结合并拮抗。这些化合物也可能与肾上腺素受体α1B结合并拮抗。这些化合物可能在治疗中发挥作用，例如（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠重吸收。这些化合物也可用于治疗对降低血压有反应或预期会有反应的疾病或症状。特别描述了使用这些化合物治疗心血管和肾脏疾病。
• Studies on Cognitive Enhancing Agents. II. Antiamnestic and Antihypoxic Activities of 1-Aryl-2-(2-aminoethoxy)ethanols.
  作者：Satoshi ONO、Tetsuo YAMAFUJI、Hisaaki CHAKI、Hajime MORITA、Yozo TODO、Mutsuko MAEKAWA、Kazunori KITAMURA、Masaru TAI、Hirokazu NARITA

  DOI：10.1248/cpb.43.1488

  日期：——

  A series of 2-(2-aminoethoxy)-1-phenylethanols having a variety of N- and phenyl-substitution patterns as well as 5- and 6-membered heteroaryl counterparts of our prototype compound 1 (2-(2-dimethylaminoethoxy)-1-phenylethanol) have been prepared and evaluated for antiamnestic and antihypoxic activities. Compound 3b, the 3-methylphenyl analogue of 1, proved to be significantly more potent than 1 in reversing eelctroconvulsive shock-induced amnesia as well as CO2-induced learning-impairment in mice. It exhibited low acute toxicity in mice and afforded a greater brain/serum concentration ratio than 1 after oral administration to rats.

  一系列具有多种N-和苯基取代模式的2-(2-氨基乙氧基)-1-苯乙醇及其5-和6元异芳烃对应化合物已经被合成并评估了其抗遗忘和抗缺氧活性。化合物3b，即1的3-甲基苯基类似物，在逆转电休克引起的健忘症及CO2诱导的小鼠学习障碍方面的效力显著高于1。它在小鼠中表现出低急性毒性，并且在口服给药后比1在大鼠中提供了更高的脑/血清浓度比。

表征谱图